Marco Gerlinger

Delighted to host our collaborators @DrHongchengZhu and Dr Xia from Fudan University Hospital at @BartsGI_Cancer this week. Working with Prof @MarcoGerlinger, and Drs @LucyKFlanders, Lerner & Nenclares to improved organ preservation strategies in rectal cancer: 40-50% is in reach

🔥Just opened: 4 year CLINICAL LECTURERSHIP position in HISTOPATHOLOGY @NHSBartsHealth and my lab @QMBCI in London: for ST3/4 registrars who already hold a PhD/MD. Great opportunity for a deep dive into the immunobiology of MMRd cancer. Deadline 11/04 10am oriel.nhs.uk/Web/Vacancy/Va…

Still time to register for our free @AACR IO webinar today: “Tumour Mutation Burden, Heterogeneity and Immunotherapy Efficacy”with Profs Jaffe, Quezada and Wargo aacr.org/meeting/aacr-i…

Join the discussion: Pervasive Cellular Plasticity intertwined with Darwinian Evolution in Cancer - does this need a new Evolutionary Theory? See our review just out in @trendscancer sciencedirect.com/science/articl…

Touched down in Miami for the 2024 @CCAlliance #CureCRC Summit - very exciting to be here again to help make this cancer history. Well prepared after lovely Christmas dinner and afternoon tea (‼️‼️) on board of the A380 💪💪💪

Starting from International Exchange Award between UK and China supported by @royalsociety, more exciting opportunities have been discussed for collaboration in clinical and translational research between the two premier centers in London and Shanghai 🇬🇧🇨🇳

Kickoff meeting of our new St Barts Hospital - Fudan University Cancer Centre Oesophageal Cancer Research Collaboration in Shanghai today and yesterday. Very grateful to @RoyalSociary for funding this project which is led by Prof @MarcoGerlinger and Prof Zhen Zhang

Outstanding session with @elena_elez and @BenjcRousseau on immunotherapy biomarkers at @ASCO #ASCO24 this morning. Key messages: Exciting and powerful new IO biomarkers on the horizon. We now need to apply them to large clinical trials including those from industry.

Great talk on chromosomal instability by my @QMBCI colleague Dr McClelland @McclellandLab at #AACR24 @AACR in RM29 ongoing

.@politikaterina will be presenting during the Lineage Plasticity in Tumor Evolution and Acquired Resistance educational session at #AACR24, this morning at 8am PST/11am EST. abstractsonline.com/pp8/#!/20272/s… @SmilowCancer @YaleMed @YNHH @yalepathology @YaleThoracic

What is the role of the TME in lung cancer evolution? We are excited to share our new TRACERx paper “Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer” at #AACR24, out in @CD_AACR today rb.gy/q484j9 Tweetorial👇

.@JeffTownsend discussed how the evolution of #cancer is rarely linear, but a branching model that influences progression #AACR24 “Every one of our bodies has a tree of history underlying every cell in our body.” #phylogenetics @AACR @SmilowCancer @YaleMed @YaleSPH

Looking forward to meet for a drink (and science discussion of course…)

Important POSTER SESSIONS For those of you at #AACR24: 👉🏻Tumor Evolution in Space and Time is on Monday 9am-12:30 (section 12) 👉🏻Tumor Evolution Models and Technologies on Tuesday 9am-12:30 (section 13) We received 🏅outstanding 🥇 abstracts this year. Don‘t miss out!!

What a great start of 2024! Excited, happy and proud to share our latest work published today #openaccess @NatureMedicine on the PANDA trial: neoadjuvant atezo+chemo in pts with gastric/GEJ cancers followed by surgery. Some of the key findings below. 1/10 nature.com/articles/s4159…

We're delighted that Prof Tom Powles (@tompowles1) has been selected as one of @Nature's 10 people who shaped science for his transformative clinical work delivering a life-extending treatment for severe bladder cancer. A huge honour – congratulations to Tom and his team 👏👏👏

It’s a great honour to be part of the @CCAlliance inaugural #CureCRCsummit this week. Brainstorming strategies to cure #colorectal cancer with giants in the field Drs @skopetz, Batlle, Venook, Lenz, @MyriamChalabi, @AndreaCercek + many others

Important point made in an article in @guardian today: better outcomes for cancer patients who are treated in research active hospitals

-Parallel evolution which surpasses even that in RCC! -Big headache for biomarker development! Our study on ITH in dMMR CRCs is out: bit.ly/3SHtxjX High mutation supply and strong immune selection pressures make this a great model tumor for #CancerEvo studies

@BartsGI_Cancer @tompowles1 An absolutely amazing result that transforms bladder cancer management. Congratulations Tom!

👏👏👏 Barts consultant Prof @tompowles1 just interrupted by applause and cheers during his presentation of ground-breaking results of Efortumab-vedotin + pembro in bladder cancer at the #ESMO23 presidential session in Madrid